Seres Therapeutics (NASDAQ:MCRB) Releases Earnings Results

Seres Therapeutics (NASDAQ:MCRB) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($1.63) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.63), FiscalAI reports. Seres Therapeutics had a negative net margin of 2,209.55% and a negative return on equity of 175.40%. The firm had revenue of $0.59 million during the quarter, compared to analysts’ expectations of $6.35 million.

Seres Therapeutics Price Performance

Shares of NASDAQ:MCRB traded down $0.10 during trading on Friday, hitting $1.99. 67,409 shares of the company were exchanged, compared to its average volume of 71,167. The firm’s 50 day moving average price is $3.40 and its 200-day moving average price is $6.91. Seres Therapeutics has a 12-month low of $1.67 and a 12-month high of $29.98. The stock has a market capitalization of $19.98 million, a P/E ratio of -0.40 and a beta of 0.44.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MCRB. Wall Street Zen raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Weiss Ratings lowered Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 18th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $17.00.

About Seres Therapeutics

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.